Di-substituted amides for enhancing glutamatergic synaptic responses
View Patent ↗This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke-induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.
1. A compound according to the formula:
wherein:
W is oxygen;
X, Y and Z are each independently —CR,
wherein:
R is H, —Br, —Cl, —F, —CN, —NO 2 , —OR 1 , —SR 1 , —NR 1 2 , —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted,
wherein:
R 1 is H, —C 1 -C 6 branched or un-branched alkyl which, may be un-substituted or substituted,
F═O or S,
A is H, or —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, —C 3 -C 7 cycloalkyl which may be un-substituted or substituted, —C 3 -C 7 alkylcycloalkyl which may be un-substituted or substituted, aryl or heterocycle which may be un-substituted or substituted, alkylaryl which may be un-substituted or substituted, alkylheterocycle which may be un-substituted or substituted
n=0, 1, 2, 3, 4, 5, or 6;
is a —C 3 -C 7 cycloalkyl which may be un-substituted or substituted, a —C 4 -C 7 azacycloalkyl, which may be un-substituted or substituted, a —C 7 -C 10 bicycloalkyl which may be un-substituted or substituted, a —C 7 -C 10 azabicycloalkyl which may be un-substituted or substituted, aryl which may be un-substituted or substituted or a heterocycle which may be un-substituted or substituted;
B is —C═, C—R a , O, N, S, C═O, S═O or SO 2 ;
R a is H, a halogen (preferably F), OH, Oalkyl, cyano, or a —C 1 -C 6 alkyl group which is un-substituted or substituted and which optionally, forms a C 3 -C 7 cycloalkyl group with D; and
D is absent when B is O, S, C═O, S═O or SO 2 , or if present, is bonded to B when B is —C═, —C—R a or N, and is H, a halogen (preferably F), OR b , a —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted and which optionally, forms a C 3 -C 7 cycloalkyl group with R a , a
—C 2 -C 6 branched or un-branched alkenyl, which may be un-substituted or substituted, a —C 2 -C 6 branched or un-branched alkynyl, which may be un-substituted or substituted, a —C 3 -C 7 cycloalkyl which may be un-substituted or substituted, an aryl which may be un-substituted or substituted, a heterocycle which may be un-substituted or substituted, a —C 2 -C 7 carboxyalkyl which may be un-substituted or substituted, a carboxyaryl which may be un-substituted or substituted, a carboxyheteroaryl which may be un-substituted or substituted, a —C 1 -C 7 sulfonylalkyl which may be un-substituted or substituted, a sulfonylaryl which may be un-substituted or substituted or a sulfonylheteroaryl which may be un-substituted or substituted, or when B is —C—R a , R a and D optionally form a ═N—R c or a ═N—OR c group with B, wherein R c is H or an unsubstituted or substituted C 1 -C 7 alkyl group; and
R b is H, a —C 1 -C 7 alkyl group which may be branched or un-branched, un-substituted or substituted or a —C 2 -C 7 acyl group which may be un-substituted or substituted;
or a pharmaceutically acceptable salt or pro-drug thereof.
2. Compounds of claim 1 according to formula II:
wherein:
A is —C 1 -C 6 branched or un-branched alkyl, which may be un-substituted or substituted, a —C 3 -C 7 cycloalkyl which may be un-substituted or substituted;
n is 0, 1, 2, or 3; and
B is C—R a , C═O or O;
R a is H, OH, alkyl or F; and
D is absent, is H or OH when R a is H or alkyl, or is F when R a is F, or a pharmaceutically acceptable salt thereof.
3. Compounds of claim 1 according to formula III:
wherein:
A is a C 1 -C 6 alkyl which may be substituted or un-substituted
B is C—R a , O or C═O;
R a is H, F, —OH or alkyl and
D is absent (when B is O), is H or OH when R a is H or alkyl, or is F when R a is F, or a pharmaceutically acceptable salt thereof.
4. Compounds of claim 1 according to formula IV:
wherein:
A is a C 1 -C 6 alkyl which may be substituted or un-substituted,
n is 0, 1 or 2, or a pharmaceutically acceptable salt thereof.
5. Compounds of claim 1 according to formula V:
wherein:
A is a C 1 -C 6 alkyl which may be substituted or un-substituted,
R 1 is H, F, or C 1 -C 4 alkyl,
R 2 is H, F, CN, a heterocycle which may be substituted or un-substituted or OR 3 ,
R 3 is H, C 1 -C 6 alkyl which may be substituted or un-substituted, or a pharmaceutically acceptable salt thereof.
6. Compounds of claim 1 according to formula VI:
wherein:
A is a C 1 -C 6 alkyl which may be substituted or un-substituted,
R is H, or C 1 -C 4 alkyl, or a pharmaceutically acceptable salt thereof.
7. Compounds of claim 1 according to formula VII:
wherein:
B is C—R a , O or C═O;
R a is H, F, —OH or alkyl and
D is absent (when B is O), is H or OH when R a is H or alkyl, or is F when R a is F, or a pharmaceutically acceptable salt thereof.
8. Compounds of claim 1 according to formula VIII:
wherein:
B is C—R a , O or C═O;
R a is H, F, —OH or alkyl and
D is absent (when B is O), is H or OH when R a is H or alkyl, or is F when R a is F, or a pharmaceutically acceptable salt thereof.
9. Compounds of claim 1 according to formula IX:
wherein:
A is a C 1 -C 6 alkyl which may be substituted or un-substituted,
R 1 is H, or C 1 -C 4 alkyl,
R 2 is H, or a C 1 -C 6 alkyl which may be substituted or un-substituted,
R 3 is H, or a C 1 -C 6 alkyl which may be substituted or un-substituted,
R 4 is H, or a C 1 -C 6 alkyl which may be substituted or un-substituted, or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 1 which is:
N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclopentyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide or
N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.
11. A compound according to Formula IX of claim 9 which is:
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl N,N-dimethyl glycinate hydrochloride
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl L-alaninate hydrochloride
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl L-valinate hydrochloride
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexyl N,N-dimethyl glycinate hydrochloride
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]-1-methylcyclohexyl glycinate hydrochloride or
trans-4-[(2,1,3-Benzoxadiazol-5-ylcarbonyl)(methyl)amino]cyclohexyl glycinate hydrochloride.
12. A compound according to claim 1 which is:
N-Cycloheptyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(4,4-Dimethylcyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-spiro[2.5]oct-6-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclobutyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclohexyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclopentyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclobutyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-D 3 -Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(Tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(Tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(tetrahydro-2H-pyran-3-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Ethyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclohexyl-N-ethyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(Cyclohexylmethyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Benzyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(tetrahydrofuran-2-ylmethyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-pyridin-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-phenyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Cyclopropyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Tetrahydro-2H-pyran-4-yl-N-(2,2,2-trifluoroethyl)-[2,1,3]-benzoxadiazole-5-carboxamide tert-Butyl-4-[([2,1,3]-benzoxadiazol-5-ylcarbonyl)(methyl)amino]piperidine-1-carboxylate
N-Methyl-N-piperidin-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide hydrochloride
N-Methyl-N-(1-methylpiperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(1-Acetylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(1-Formylpiperidin-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-[1-(methylsulfonyl]piperidin-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(tetrahydro-2H-pyran-4-yl)-[2,1,3]-benzothiadiazole-5-carboxamide
N-Methyl-N-(tetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(1-oxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide N-Methyl-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-tetrahydro-2H-pyran-4-ylquinoxaline-6-carboxamide
N-[4-(Hydroxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-[4-(Methoxyimino)cyclohexyl]-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(4,4-Difluorocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(4-fluorocyclohex-3-en-1-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(4-trans-Hydroxycyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Hydroxy-4-methylcyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Hydroxy-4-ethylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-4-Ethynyl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-But-3-en-1-yl-4-hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(4-trans-Hydroxycyclohexyl)-N-D 3 -methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Methoxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carbothioamide
N-(4-cis-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-[trans-4-(2H-tetrazol-2-yl)cyclohexyl]-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Azidocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-4-Aminocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(cis-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-(trans-3-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(3-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(3,3-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(2-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(2-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(2,2-difluorocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(2-Hydroxytetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-(2-oxotetrahydro-2H-pyran-4-yl)-[2,1,3]-benzoxadiazole-5-carboxamide
N-(2-Hydroxytetrahydro-2H-pyran-4-yl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide
N—(R)-Tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N—(R)-tetrahydrofuran-3-yl-[2,1,3]-benzoxadiazole-5-carboxamide
N-2-(4-Morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide
N-Methyl-N-2-(4-morpholinyl)ethyl-[2,1,3]-benzoxadiazole-5-carboxamide hydrochloride
N-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carbothioamide or
N-Methyl-N-tetrahydro-2H-pyran-4-ylmethyl-[2,1,3]-benzoxadiazole-5-carboxamide.
13. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1 - 12 in combination with a pharmaceutically acceptable carrier, additive or excipient.
14. The composition according to claim 13 wherein said compound comprises about 0.5% to about 75% by weight of said composition and said carrier, additive or excipient comprises about 25% to about 95.5% of said composition.
15. The compound according to claim 10 which is N-Cyclohexyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.
16. The compound according to claim 10 which is N-Cyclopentyl-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.
17. The compound according to claim 10 which is N-(trans-4-Cyanocyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.
18. The compound according to claim 10 which is N-Methyl-N-tetrahydro-2H-pyran-4-yl-[2,1,3]-benzoxadiazole-5-carboxamide.
19. The compound according to claim 10 which is N-Methyl-N-(4-oxocyclohexyl)-[2,1,3]-benzoxadiazole-5-carboxamide.
20. The compound according to claim 10 which is N-(trans-4-Hydroxy-4-methylcyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.
21. The compound according to claim 10 which is N-(4-trans-Hydroxycyclohexyl)-N-methyl-[2,1,3]-benzoxadiazole-5-carboxamide.